An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Inclusion Criteria: * msSBP (mean of 3 systolic blood pressure measurements) must be ≥ 95th percentile for age, gender and height, at Visit 2 (randomization), in study CSPP100A2365 * Must be ≥ 20 kg and ≤ 150 kg at Visit 2 (randomization), in study CSPP100A2365 * Must be able to swallow minitablets (2mm in diameter) administered in soft food * Successful completion of Phase 1 (dose response phase) and at least 1 week of Phase 2 (placebo withdrawal phase) of the CSPP100A2365 protocol, with no serious drug-related adverse event(s). Exclusion Criteria: * Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than oral/topical steroids, for any medical condition * Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or obstructive valvular disease * msSBP ≥ 25% above the 95th percentile * Second or third degree heart block without a pacemaker * AST/SGOT or ALT/SGPT \>3 times the upper limit of the reference range * Total bilirubin \> 2 times the upper limit of the reference range * Creatinine clearance \< 30 mL/min/1.73m² (calculated using Modified Schwartz formula to estimate glomerular filtration rate \[GFR\]), based on the serum creatinine concentration obtained at the screening visit) * WBC count \< 3000/mm³ * Platelet count \< 100,000/mm³ * Serum potassium \> 5.2 mEq/L * Other protocol-defined inclusion/exclusion criteria may apply